Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Accumulated Expenses: 2011-2024

Historic Accumulated Expenses for Niagen Bioscience (NAGE) over the last 11 years, with Dec 2024 value amounting to $7.8 million.

  • Niagen Bioscience's Accumulated Expenses fell 9.30% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year decrease of 9.30%. This contributed to the annual value of $7.8 million for FY2024, which is 17.66% down from last year.
  • Niagen Bioscience's Accumulated Expenses amounted to $7.8 million in FY2024, which was down 17.66% from $9.5 million recorded in FY2023.
  • In the past 5 years, Niagen Bioscience's Accumulated Expenses registered a high of $9.5 million during FY2023, and its lowest value of $6.1 million during FY2020.
  • Moreover, its 3-year median value for Accumulated Expenses was $7.8 million (2024), whereas its average is $8.2 million.
  • In the last 5 years, Niagen Bioscience's Accumulated Expenses skyrocketed by 38.91% in 2020 and then fell by 17.66% in 2024.
  • Yearly analysis of 5 years shows Niagen Bioscience's Accumulated Expenses stood at $6.1 million in 2020, then grew by 5.67% to $6.5 million in 2021, then climbed by 13.21% to $7.3 million in 2022, then increased by 29.39% to $9.5 million in 2023, then declined by 17.66% to $7.8 million in 2024.